Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II rollover safety study of oral brigimadlin in solid tumours
jRCT2031240625Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of brigimadlin in Nonhematologic neoplasms (2 cohorts), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events. Started Jan 2025; status: active, not recruiting.
02
Drugs
brigimadlin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031240625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240625.